Evidence map›Paper›PMID 21252674›Full record

ReviewCurrent opinion in pediatrics2011

Biomarkers for the early detection of acute kidney injury.

Prasad Devarajan

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Current opinion in pediatrics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04759599 (Which is Better), which is not on this map. Cited by 136 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
136citing papers in PubMed, 7 pooled it
13.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04759599 naunknown statusnot on this mapstarted 2021, after this paper: background citation

Which is Better: Narrow vs. Wide Focus for Shock Wave Lithotripsy of Renal Stones

TypeinterventionalSponsorBenha UniversityRan2021 to 2023Enrolled140ConditionsRenal Stone, Treatment Side EffectsArmsShock Wave Lithotripsy (SWL)
3 · Its place in the literature

Who cites it

136 citing papers in PubMed, 7 syntheses or guidelines pooled it, 278 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Performance of urinary liver-type fatty acid-binding protein in acute kidney injury: a meta-analysis.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2013
    Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Biomarkers for early detection of sickle nephropathy.American journal of hematology · 2011
    Trial
  13. Article
  14. Article
  15. Review
  16. Review
  17. Observational
  18. Review
  19. Article
  20. Urinary biomarkers of diabetic kidney disease.World journal of diabetes · 2026
    Review

76 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Prasad DevarajanCenter for Acute Care Nephrology, Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Cincinnati, Ohio 45229-3039, USA. prasad.devarajan@cchmc.org
Cincinnati Children's Hospital Medical Center · US

Funding

Implications of the ASK1/JNK pathway in ARFR01DK069749 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI DEVARAJAN, PRASAD · 2005 to 2009
$1.6M
ANKYRIN: CRUCIAL LINKER IN RENAL CELL APOPTOTIC CASCADESR01DK053289 · NIDDK · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI DEVARAJAN, PRASAD · 2000 to 2003
$674k
NGAL: A novel early biomarker of acute renal injuryR21DK070163 · NIDDK · CHILDREN'S HOSPITAL MED CTR (CINCINNATI) · PI DEVARAJAN, PRASAD · 2004 to 2005
$410k
NIDDK NIH HHS R01 DK053289NIDDK NIH HHS R01 DK069749NIDDK NIH HHS R01 DK53289NIDDK NIH HHS R21 DK070163
6 · The paper itself

Abstract

purpose of reviewAcute kidney injury (AKI) is a common and serious condition, the diagnosis of which depends on serum creatinine, which is a delayed and unreliable indicator of AKI. Fortunately, understanding the early stress response of the kidney to acute injuries has revealed a number of potential biomarkers. The current status of the most promising of these novel AKI biomarkers, including neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), liver-type fatty acid binding protein (L-FABP), and interleukin (IL)-18, is reviewed. RECENT

findingsIn particular, NGAL is emerging as an excellent biomarker in the urine and plasma, for the early prediction of AKI, for monitoring clinical trials in AKI, and for the prognosis of AKI in several common clinical scenarios. However, biomarker combinations may be required to improve our ability to predict AKI and its outcomes in a context-specific manner. SUMMARY: It is vital that additional large future studies demonstrate the association between biomarkers and hard clinical outcomes independent of serum creatinine concentrations and that randomization to a treatment for AKI based on high biomarker levels results in an improvement in clinical outcomes.

Indexed as

Acute Kidney InjuryAcute-Phase ProteinsBiomarkersChildEarly DiagnosisFatty Acid-Binding ProteinsHepatitis A Virus Cellular Receptor 1HumansInterleukin-18Lipocalin-2LipocalinsMembrane GlycoproteinsProto-Oncogene ProteinsReceptors, VirusAcute-Phase ProteinsBiomarkersFABP1 protein, humanFatty Acid-Binding ProteinsHAVCR1 protein, humanHepatitis A Virus Cellular Receptor 1Interleukin-18LCN2 protein, humanLipocalin-2LipocalinsMembrane GlycoproteinsProto-Oncogene ProteinsReceptors, Virus

Identifiers

PMID21252674
PMCPMC3257513
OpenAlexW1997758474

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.